TransCode Therapeutics Reports TTX-MC138 Survival Benefit in Preclinical Breast Cancer Bone Metastasis Study

TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company focused on developing RNA-based therapeutics for high-risk and advanced cancers, has announced the publication of a peer-reviewed article in Cancers detailing preclinical results for its lead therapeutic candidate, TTX-MC138, in a model of breast cancer bone metastasis. The study demonstrated that TTX-MC138, following systemic administration, accumulated in metastatic bone lesions, reduced expression of microRNA-10b (miR-10b), increased expression of the downstream tumor-suppressor target HOXD10, and produced significant survival benefits compared with controls. Importantly, repeated dosing was well tolerated with no observed systemic toxicity.

These findings further support TransCode's approach of inhibiting miR-10b using its proprietary oligonucleotide nanotechnology and suggest potential applicability across additional metastatic disease settings. This is particularly relevant for Texas, where cancer research and biotechnology innovation are integral to the state's economy. The potential of TTX-MC138 to address metastatic cancers, which are responsible for the majority of cancer-related deaths, could have far-reaching implications for patients and the healthcare industry.

The study's results are a critical step in validating the therapeutic potential of targeting miR-10b, a well-documented biomarker of metastasis. By demonstrating that TTX-MC138 can effectively reduce miR-10b expression in metastatic lesions and improve survival, TransCode provides evidence that this approach could be developed into a viable treatment option for patients with advanced cancers, particularly those with bone metastases.

For the biotechnology sector, these findings highlight the promise of RNA-based therapeutics and nanotechnology in oncology. They also underscore the importance of continued investment in research and development to bring such innovative treatments to market. For investors and stakeholders, the publication of these results in a peer-reviewed journal adds credibility to TransCode's pipeline and could influence the company's future development plans.

TransCode Therapeutics is pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. Its lead candidate, TTX-MC138, is designed to treat metastatic tumors that overexpress miR-10b. The company also has a portfolio of other first-in-class therapeutic candidates aimed at mobilizing the immune system to recognize and destroy cancer cells.

The full press release can be viewed at https://ibn.fm/E6gbq. For the latest news and updates regarding TransCode Therapeutics, visit their newsroom at https://ibn.fm/RNAZ.